Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2022-05-04 | 2022-03 | -0.46 | N/A | N/A | N/A |
2022-03-14 | 2021-12 | -0.31 | N/A | N/A | N/A |
2021-11-10 | 2021-09 | -0.29 | N/A | N/A | N/A |
2021-08-11 | 2021-06 | -0.28 | N/A | N/A | N/A |
2021-05-05 | 2021-03 | -0.29 | N/A | N/A | N/A |
2021-04-05 | 2020-12 | -0.37 | N/A | N/A | N/A |
Date | Firm | Action | From | To |
---|---|---|---|---|
2021-03-03 | Cantor Fitzgerald | Upgrade | Overweight | |
2020-10-14 | B. Riley FBR | Upgrade | Buy | |
2020-02-06 | Maxim Group | Upgrade | Buy | |
2019-07-30 | Brookline Capital | Upgrade | Buy | |
2018-06-26 | H.C. Wainwright | Upgrade | Buy | |
2016-06-20 | Roth Capital | Upgrade | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2018-12-31 | HUTCHINS JEFF TOBIN PH.D. | Officer | 143.14K | Stock Award(Grant) |
2020-08-12 | OSTRANDER WILLIAM L. | Officer | 11.19K | Conversion of Exercise of derivative security |
2020-01-01 | PRENDERGAST JOHN K. A. PH.D. | Director | 700.00K | Stock Award(Grant) |
2018-12-31 | ROSAR ANN A | Officer | 93.38K | Stock Award(Grant) |
2020-11-11 | SMITH EDWARD B III | Director | 0.00 | Sale |
2020-01-01 | WOLF JEFFREY ALAN J.D. | Chief Executive Officer | 3.94M | Stock Award(Grant) |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2022-03-30 | Vanguard Group, Inc. (The) | 1.10M | 3.36M | 4.32% |
2022-03-30 | Blackrock Inc. | 471.91K | 1.44M | 1.86% |
2022-03-30 | Geode Capital Management, LLC | 249.54K | 763.59K | 0.98% |
2022-03-30 | LPL Financial LLC | 133.05K | 407.15K | 0.52% |
2022-03-30 | State Street Corporation | 102.98K | 315.13K | 0.41% |
2022-03-30 | Morgan Stanley | 75.94K | 232.36K | 0.30% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2021-12-30 | Vanguard Total Stock Market Index Fund | 705.53K | 2.14M | 2.78% |
2021-12-30 | Vanguard Extended Market Index Fund | 353.50K | 1.07M | 1.39% |
2022-02-27 | Fidelity Extended Market Index Fund | 159.44K | 414.54K | 0.63% |
2022-01-30 | iShares Micro Cap ETF | 60.31K | 176.11K | 0.24% |
2022-02-27 | IndexIQ ETF Tr-IQ Chaikin U.S. Small Cap ETF | 57.97K | 150.71K | 0.23% |
2022-01-30 | DFA U.S. Small Cap Series | 41.17K | 120.20K | 0.16% |
Split | Date |
---|---|
1 : 7 | 2020-12-11 |
1 : 10 | 2018-01-22 |
-
-
-
Specifically, Heat announced that its COVID-19 vaccine candidate exhibited compelling evidence of immunogenicity (the ability to provoke a body's immune response) in a preclinical (animal) study. Although the biotech's shares have cooled off a bit over the course of today's session, they are still up by a noteworthy 20% as of 10:56 a.m. EDT.
-
-
Gonna fly
-
-
-
-
Seems like a good day with new news. https://www.google.com.mt/amp/s/seekingalpha.com/amp/news/3596617-heat-biologics-covidminus-19-vaccine-shows-encouraging-action-in-preclinical-study
-
Heat Biologics COVID-19 vaccine shows encouraging action in preclinical study
Jul. 29, 2020 7:59 AMHeat Biologics, Inc. (HTBX)By: Douglas W. House, SA News Editor
Heat Biologics (NASDAQ:HTBX) announces results from preclinical testing of its COVID-19 vaccine candidate -
-
-
-
Itβs a good stock with big potential, and august PR is coming soon, Heat Biologics Inc (HTBX) stock is higher by 1.99% while the S&P 500 is unmoved 0% as of 9:59 AM on Monday, Jul 27. HTBX is higher by $0.05 from the previous closing price of $2.51 on volume of 3,636,925 shares. Over the past year the S&P 500 has risen 6.44% while HTBX is higher by 392.31%. HTBX lost -$0.54 per share in the over the last 12 months
-
Analyst's Opinion
Consensus Rating
Heat Biologics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/Downside
According to analysts' consensus price target of $5.00, Heat Biologics has a potential upside of 131.5% from its current price of $2.16. -
See you at 3$
-
-